Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

---

Armstrong P. W., Pieske B., Anstrom K. J., Ezekowitz J., Hernandez A. F., Butler J., ...Daha Fazla

NEW ENGLAND JOURNAL OF MEDICINE, cilt.382, sa.20, ss.1883-1893, 2020 (SCI-Expanded)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 382 Sayı: 20
• Basım Tarihi: 2020
• Doi Numarası: 10.1056/nejmoa1915928
• Dergi Adı: NEW ENGLAND JOURNAL OF MEDICINE
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Abstracts in Social Gerontology, AgeLine, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, Educational research abstracts (ERA), EMBASE, Food Science & Technology Abstracts, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, MLA - Modern Language Association Database, Public Affairs Index, Veterinary Science Database
• Sayfa Sayıları: ss.1883-1893
• Dokuz Eylül Üniversitesi Adresli: Hayır

Özet

BackgroundThe effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear.